Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 358

1.

Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.

Fujino H, Tanaka M, Imamura M, Morio K, Ono A, Nakahara T, Murakami E, Kawaoka T, Takahashi S, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K.

BMC Gastroenterol. 2019 Oct 24;19(1):169. doi: 10.1186/s12876-019-1092-z.

2.

Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.

Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN, Chayama K.

J Med Virol. 2019 Oct 4. doi: 10.1002/jmv.25602. [Epub ahead of print]

PMID:
31584207
3.

Organic anion transporting polypeptide (OATP) genes are not induced by the pregnane X receptor (PXR) activator rifampin: studies in hepatocytes in vitro and in monkeys in vivo.

Niu C, Wang Y, Zhao X, Tep S, Murakami E, Subramanian R, Smith B, Lai Y.

Drug Metab Dispos. 2019 Oct 3. pii: dmd.119.088922. doi: 10.1124/dmd.119.088922. [Epub ahead of print]

4.

Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

Namba M, Hiramatsu A, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Tsuge M, Imamura M, Chayama K.

J Gastroenterol. 2019 Sep 4. doi: 10.1007/s00535-019-01623-4. [Epub ahead of print]

PMID:
31485782
5.

Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

Ohya K, Imamura M, Osawa M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Hiramatsu A, Tsuge M, Aikata H, Hayes CN, Chayama K.

Clin J Gastroenterol. 2019 Aug 28. doi: 10.1007/s12328-019-01039-w. [Epub ahead of print]

PMID:
31463795
6.

Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy.

Ohya K, Kawaoka T, Namba M, Uchikawa S, Kodama K, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Yamauchi M, Imamura M, Chayama K, Aikata H.

Sci Rep. 2019 Aug 20;9(1):12101. doi: 10.1038/s41598-019-48045-z.

7.

Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.

Kodama K, Kawaoka T, Namba M, Uchikawa S, Ohya K, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Imamura M, Chayama K, Aikata H.

Oncology. 2019;97(2):75-81. doi: 10.1159/000499715. Epub 2019 Jun 26.

PMID:
31242488
8.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.

Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K.

J Gen Virol. 2019 Jul;100(7):1123-1131. doi: 10.1099/jgv.0.001268. Epub 2019 Jun 14.

PMID:
31199224
9.

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K.

Jpn J Clin Oncol. 2019 Aug 1;49(8):762-765. doi: 10.1093/jjco/hyz066.

PMID:
31090906
10.

Feasibility of Trypsin Digestion as a Sample Preparation for Daptomycin Quantification in Murine Skeletal Muscles.

Sakai Y, Murakami E, Kato H, Ohyama K, Esaka Y, Yamamoto T, Hagihara M, Mikamo H, Uno B.

Biol Pharm Bull. 2019;42(5):751-757. doi: 10.1248/bpb.b18-00945.

11.

Characterizing standard genetic parts and establishing common principles for engineering legume and cereal roots.

Feike D, Korolev AV, Soumpourou E, Murakami E, Reid D, Breakspear A, Rogers C, Radutoiu S, Stougaard J, Harwood WA, Oldroyd GED, Miller JB.

Plant Biotechnol J. 2019 Dec;17(12):2234-2245. doi: 10.1111/pbi.13135. Epub 2019 May 23.

12.

The association between sacroiliac joint-related pain following lumbar spine surgery and spinopelvic parameters: a prospective multicenter study.

Tonosu J, Kurosawa D, Nishi T, Ito K, Morimoto D, Musha Y, Ozawa H, Murakami E.

Eur Spine J. 2019 Jul;28(7):1603-1609. doi: 10.1007/s00586-019-05952-z. Epub 2019 Mar 18.

PMID:
30887220
13.

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis.

Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, Inagaki Y, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, Tanaka J, Chayama K.

Hepatol Commun. 2019 Jan 22;3(3):348-355. doi: 10.1002/hep4.1309. eCollection 2019 Mar.

14.

Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice.

Tsushima K, Tsuge M, Hiraga N, Uchida T, Murakami E, Makokha GN, Kurihara M, Nomura M, Hiyama Y, Fujino H, Ono A, Nakahara T, Yamauchi M, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Aikata H, Hayes CN, Chayama K.

J Gastroenterol. 2019 Jul;54(7):650-659. doi: 10.1007/s00535-019-01558-w. Epub 2019 Feb 21.

PMID:
30790056
15.

Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis.

Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, Liu H.

J Feline Med Surg. 2019 Apr;21(4):271-281. doi: 10.1177/1098612X19825701. Epub 2019 Feb 13.

16.

Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.

Namba M, Kawaoka T, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Baba Y, Awai K, Chayama K.

Clin J Gastroenterol. 2019 Aug;12(4):341-346. doi: 10.1007/s12328-019-00938-2. Epub 2019 Jan 31.

PMID:
30706429
17.

Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.

Antivir Ther. 2019;23(8):709. doi: 10.3851/IMP3289. No abstract available.

PMID:
30632982
18.

Corrigendum to "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab" [Lung Cancer 115 (2018) 71-74].

Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N.

Lung Cancer. 2018 Dec;126:230-231. doi: 10.1016/j.lungcan.2018.11.007. Epub 2018 Nov 18. No abstract available.

19.

Early experience of seven hepatocellular carcinoma cases treated with regorafenib.

Uchikawa S, Kawaoka T, Aikata H, Kodama K, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K.

Clin Case Rep. 2018 Oct 11;6(11):2217-2223. doi: 10.1002/ccr3.1791. eCollection 2018 Nov.

20.

Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.

Osawa M, Imamura M, Teraoka Y, Uchida T, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K; Hiroshima Liver Study Group.

J Gastroenterol. 2019 Mar;54(3):291-296. doi: 10.1007/s00535-018-1520-9. Epub 2018 Oct 17.

PMID:
30334096

Supplemental Content

Loading ...
Support Center